Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 5, 1998, Pages 363-366

  Wurz, Gregory T ^a   Soc, Lin ^a   Emshoff, Vernon D ^a   Cadman, Timothy B ^a   DeGregorio, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Doxorubicin; Drug interaction; MDR; Toremifene

Indexed keywords

DOXORUBICIN; TOREMIFENE;

AREA UNDER THE CURVE; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MEGADOSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; TOREMIFENE;

EID: 0031691146     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050830     Document Type: Article

References (24)

1. Angley MT, Sansom LN, Stupans I (1995) Cyclophosphamide administered repeatedly to the male rat and as a single dose to the female rat. Its effects on hepatic and pulmonary P450 and associated enzymes. Xenobiotica 25(10): 1051
2. Cornwell MM, Gottesman MM, Pastan IH (1986) Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 261(17): 7921
3. DeGregorio MW, Wiebe VJ (1990) Pharmacologic management of drug-resistant genitourinary tumors. World J Urol 8: 6
4. DeGregorio MW, Carrera CJ, Klock JC, Wilbur JR (1982) Uptake and metabolism of daunorubicin by human leukemia cells. Cancer Chemother Pharmacol 10(1): 29
5. DeGregorio MW, Ford JM, Benz CC, Wiebe VJ (1989) Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7(9): 1359
6. Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC (1988) Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother Pharmacol 22(2): 147
7. Holleran WM, Gharbo SA, DeGregorio MW (1987) Quantitation of toremifene and its major metabolites in human plasma by high-performance liquid chromatography following fluorescent activation. Anal Lett 20: 871
8. Kivinen S, Mäenpää J (1990) Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase 1 study. J Steroid Biochem 36: 217
9. Kivisto KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40(6): 523
10. Liippo K, Ellmen J, Vänttinen E, Anttila M (1997) Toremifene concentration and multidrug resistance in lung tumors. Cancer Chemother Pharmacol 39: 212
11. Mirski SE, Gerlach JH, Cole SP (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47(10): 2594
12. Pichard L, Fahre I, Daujat M, Domergue J, Joyeux H, Maurel P (1992) Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 41: 1047
13. Rahmani R, Zhou XJ (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17: 269
14. Ramu A, Fuks Z, Gatt S, Glaubiger D (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res 44(1): 144
15. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T (1996) Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56(1): 58
16. Slater LM, Sweet P, Stupecky M, Wetzel MW, Gupta S (1986) Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54(2): 235
17. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug-resistant p388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42(11): 4730
18. Twentyman PR, Fox NE, Wright KA, Blechen NM (1986) Derivation and preliminary characterization of adriamycin resistant cell lines of human lung cancer cells. B J Cancer 53(4): 529
19. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW (1990) Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 25(4): 247
20. Wiebe V, Koester S, Lindberg M, Emshoff V, Baker J, Wurz G, DeGregorio M (1992) Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells. Invest New Drugs 10(2): 63
21. Wurz GT, Emshoff VD, DeGregorio MW, Wiebe VJ (1993) Targeting chemosensitizing doses of toremifene based on protein binding. Cancer Chemother Pharmacol 31(5): 412
22. Zamora JM, Pearce HL, Beck WT (1988) Physical-chemical properties shared by compounds that modulate multiple drug resistance in human leukemic cells. Mol Pharmacol 33(4): 454
23. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R (1993). Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol 45(4): 853
24. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53(21): 5121